Compare DDL & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDL | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 495.5M |
| IPO Year | 2021 | 2021 |
| Metric | DDL | VALN |
|---|---|---|
| Price | $2.40 | $5.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 348.0K | 23.8K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $14.86 | $93.87 |
| P/E Ratio | $16.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $4.75 |
| 52 Week High | $3.41 | $12.25 |
| Indicator | DDL | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 55.83 |
| Support Level | $1.86 | $5.10 |
| Resistance Level | $2.65 | $5.52 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 47.25 | 80.77 |
Dingdong (Cayman) Ltd are a foremost fresh grocery e-commerce company in mainland China with sustainable growth. It directly provide users and households with fresh groceries, prepared food and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. The Group operates and manages its business as a single segment. The Group generates substantially all of its revenues from customers in the PRC.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.